Mixed Topline Results for Anti-Tau Agent in Phase 2 Trial
The phase 2 CELIA trial of diranersen, an investigational anti-tau agent, showed promising reductions in tau levels and signals of slowed cognitive decline in early Alzheimer's disease patients. However, it did not meet its primary endpoint regarding dose response on the Clinical Dementia Rating scale. Despite this, Biogen remains optimistic about the drug's potential and plans to continue its development.
- ▪Diranersen was associated with reductions in cerebrospinal fluid tau and tau pathology.
- ▪The study enrolled 416 participants aged 50-80 with mild cognitive impairment or mild AD dementia.
- ▪The safety profile of diranersen was consistent with previous studies, although serious adverse events were higher at the highest dose.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/mixed-topline-results-anti-tau-agent-phase-2-trial-early-ad-2026a1000fyo?src=rss |
| Publication time | Mon, 18 May 2026 07:20:06 EDT |
| Retrieval time | 2026-05-18T11:34:56.486Z |
| Last seen | 2026-05-18T11:34:56.486Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | ViM26dG00xue |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Diranersen (BIIB080), an investigational antisense oligonucleotide targeting tau, was associated with robust reductions in both cerebrospinal fluid tau and tau pathology, coupled with signals of slowed clinical decline in patients with early Alzheimer’s disease (AD), topline results from the phase 2 CELIA trial showed.However, the study failed to meet its primary endpoint assessing dose response for change from baseline on the Clinical Dementia Rating-Sum of Boxes scale at 76 weeks, the manufacturer Biogen reported.Still, prespecified analyses showed slowing of cognitive decline across all studied doses, particularly among patients receiving the lowest dose of 60 mg every 24 weeks, the company said.The randomized, placebo-controlled CELIA trial enrolled 416 participants aged 50-80 years…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
